目的 对重组人干扰素α-2b联合保妇康栓治疗人乳头瘤病毒（HPV）感染进行成本-效果分析，为临床合理用药和医疗卫生决策提供循证依据。方法 从医疗保健系统角度建立决策树模型，对重组人干扰素α-2b单用（对照组）或联合保妇康栓（每次1粒或每次2粒，分别为联合用药组1和联合用药组2）治疗HPV感染进行成本-效果分析。效果指标采用Meta分析获得HPV转阴率，成本数据根据官方网站发布的药品价格和诊疗价格获得。采用单因素敏感性分析对成本-效果分析的结果进行验证。结果 对照组、联合用药组1和联合用药组2的HPV转阴率分别为66.40%、87.00%、85.11%，对应的治疗总成本分别为1 217.20、1 303.80、1 435.38元。联合用药组1与对照组相比，增量成本效果比（ICER）为393.62元，低于1倍2021年中国人均GDP（80 976.00元），联合用药组1，即重组人干扰素α-2b联合保妇康栓（每次1粒）更具有成本-效果优势。单因素敏感性分析显示，联合用药组HPV转阴率是对ICER影响最大的因素。结论 重组人干扰素α-2b联合保妇康栓（每次1粒）治疗HPV感染更具经济性。

Objective To conduct the cost-effectiveness analysis of recombinant human interferon α-2b combined with Baofukang Suppository in treatment of Human papilloma-virus (HPV), and to provide evidence-based reference for rational drug use and medical and healthy decision-making. Methods From the perspective of the healthcare system, a decision tree model was established to analyze the cost-effectiveness of recombinant human interferon α-2b singly or combined with Baofukang Suppository (1 or 2 capsules per time for combination group 1 and combination group 2, respectively). The effectiveness was obtained through Meta-analysis, and the cost was obtained according to the drug price and diagnosis and treatment price published on the official websites. Single-factor sensitivity analysis was performed to validate the results of cost-effectiveness analysis. Results The HPV negative rates of the recombinant human interferon α-2b single group (control group), the first combination group (one capsule once time), and the second combination group (two capsule once time) were 66.40%, 87.00%, and 85.11% respectively. And the corresponding total cost of treatment was separately 1 217.20 yuan, 1 303.80 yuan, and 1 435.38 yuan. Compared with the single group, the incremental cost-effect ratio (ICER) of combination group 1 was 393.62 yuan, which was less than one time the average GDP of the Chinese in 2021 (80 976.00 yuan). Therefore, the combination group 1, that is, recombinant human interferon α-2b combined with one capsule/time of Baofukang Suppository, has a cost-effect advantage. Single factor sensitivity analysis showed that the treatment effectiveness of these groups was the most important factor affecting the ICER. Conclusion The recombinant human interferon α-2b combined with one capsule/time of Baofukang Suppository is economical in the HPV treatment.

R984